Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 3/20 | 0.36 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.34 |
| ▸ | MGLL | Q99685 | 1/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 5/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 5/20 | 0.33 |
| ▸ | DPP4 | P27487 | 2/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.33 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.32 |
| ▸ | GCGR | P47871 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21749147 | 1.00 | BTK (0.36) | BTKABCB1TP53EIF2AK4MGLL | |
| SCHEMBL21775504 | 1.00 | BTK (0.36) | BTKABCB1TP53EIF2AK4MGLL | |
| SCHEMBL21775643 | 0.91 | BTK (0.36) | BTKABCB1EIF2AK4HCRTR1HCRTR2 | |
| SCHEMBL21775862 | 0.91 | BTK (0.36) | BTKABCB1EIF2AK4HCRTR1HCRTR2 | |
| SCHEMBL21775869 | 0.91 | BTK (0.36) | BTKABCB1EIF2AK4HCRTR1HCRTR2 | |
| SCHEMBL21775755 | 0.90 | ABCB1 (0.34) | BTKABCB1TP53MGLLHCRTR1 | |
| SCHEMBL21775614 | 0.90 | DGAT1 (0.40) | ABCB1DGAT1KCNH2DPP4DPP7 | |
| SCHEMBL21775744 | 0.90 | ABCG2 (0.40) | BTKABCB1EIF2AK4DGAT1KCNH2 | |
| SCHEMBL21775867 | 0.90 | DGAT1 (0.40) | ABCB1DGAT1KCNH2DPP4DPP7 | |
| SCHEMBL21775864 | 0.90 | ABCG2 (0.40) | BTKABCB1EIF2AK4DGAT1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10960007-B2 | Pharmacologically active aryl-substituted pyrazolo[1,5-a]pyrimidine derivatives | RICHTER GEDEON NYRT. (HU) | 2021-03-30 | — | — | US | disclosed |
| US-20200061068-A1 | Pharmacologically Active Aryl-Substituted Pyrazolo[1,5-a]Pyrimidine Derivatives | RICHTER GEDEON NYRT. (HU) | 2020-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200061068-A1 | Pharmacologically Active Aryl-Substituted Pyrazolo[1,5-a]Pyrimidine Derivatives | GABRA5, P2RX5, P2RY1 | BTK 2089/4885ABCB1 243/4885TP53 3700/4885 |
| US-10960007-B2 | Pharmacologically active aryl-substituted pyrazolo[1,5-a]pyrimidine derivatives | GABRA5, P2RX5, P2RY1 | BTK 2089/4885ABCB1 243/4885TP53 3700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.